Get the Stockscreener App
96.93
0.31%
0.30
Merus N V stock is traded at $96.93, with a volume of 708.20K.
It is up +0.31% in the last 24 hours and up +0.93% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$96.63
Open:
$96.8
24h Volume:
708.20K
Relative Volume:
0.30
Market Cap:
$7.35B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-24.54
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
+0.82%
1M Performance:
+0.93%
6M Performance:
+75.00%
1Y Performance:
+133.85%
1-Day Range:
$96.80
$96.94
1-Week Range:
$96.11
$96.94
52-Week Range:
$33.19
$96.94
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
96.93 | 7.33B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Aug-25-25 | Initiated | Alliance Global Partners | Buy |
| Feb-13-25 | Initiated | Piper Sandler | Overweight |
| Feb-07-25 | Initiated | Wells Fargo | Overweight |
| Nov-21-24 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Mar-28-24 | Initiated | Truist | Buy |
| Mar-04-24 | Reiterated | Needham | Buy |
| Nov-02-23 | Initiated | Canaccord Genuity | Buy |
| Aug-21-23 | Initiated | TD Cowen | Outperform |
| Aug-02-22 | Initiated | Stifel | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Needham | Buy |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-21 | Initiated | William Blair | Outperform |
| Mar-16-21 | Initiated | SVB Leerink | Outperform |
| Jun-26-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-20-19 | Resumed | Guggenheim | Buy |
| Jun-28-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Resumed | Guggenheim | Buy |
| Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
| Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
| Jun-13-16 | Initiated | Citigroup | Buy |
| Jun-13-16 | Initiated | Guggenheim | Buy |
| Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
Holocene Advisors LP Boosts Position in Merus N.V. $MRUS - MarketBeat
Boothbay Fund Management LLC Grows Holdings in Merus N.V. $MRUS - MarketBeat
Merus N.V. (NASDAQ:MRUS) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Genmab completes $6.9 billion acquisition of Merus N.V., triggers leadership changes - Investing.com Nigeria
Merus Acquired by Genmab, Leadership Changes Announced - TipRanks
Genmab Completes Acquisition of Merus N.V. to Bolster Oncology Portfolio - TipRanks
Genmab Finalizes Tender Offer for Dutch Biotech Merus - marketscreener.com
Genmab Completes Acquisition of Merus – Bolsters Portfolio with New Cancer Treatment - marketscreener.com
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - The AI Journal
Genmab: Completion of Tender Offer for Outstanding Common Shares of Merus N.V. - marketscreener.com
Genmab: Completion Of Tender Offer For Outstanding Common Shares Of Merus N.V. - TradingView — Track All Markets
Genmab Announces Completion of Tender Offer for Outstanding - GlobeNewswire
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - GlobeNewswire Inc.
Merus (NASDAQ:MRUS) VP Sells $163,370.00 in Stock - MarketBeat
How Genmab’s US$2.5 Billion Debt-Funded Merus Deal and Lymphoma Data Will Impact Genmab (CPSE:GMAB) Investors - simplywall.st
HighVista Strategies LLC Purchases 34,723 Shares of Merus N.V. $MRUS - MarketBeat
32,269 Shares in Merus N.V. $MRUS Purchased by Russell Investments Group Ltd. - MarketBeat
Insider Moves: Merus Executive Sells Significant Stock Holdings - TipRanks
(MRUS) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Genmab: How Its Combined Pipeline, Royalties & M&A Strategy Could Potentially Unlock A SOLID Upside! - Smartkarma
Stempoint Capital LP Cuts Holdings in Merus N.V. $MRUS - MarketBeat
Merus Shareholders Approve Genmab Acquisition Proposal - TipRanks
Merus shareholders approve Genmab acquisition proposal - MSN
Merus (NASDAQ:MRUS) Reaches New 12-Month HighTime to Buy? - MarketBeat
Merus NV stock hits all-time high at 96.29 USD By Investing.com - Investing.com Canada
Merus NV stock hits all-time high at 96.29 USD - Investing.com
How Genmab’s US$2.5 Billion Merus Deal Financing Could Impact Genmab (CPSE:GMAB) Investors - Yahoo Finance
Federated Hermes Inc. Has $80.40 Million Holdings in Merus N.V. $MRUS - MarketBeat
Saturn V Capital Management LP Has $11.80 Million Stock Position in Merus N.V. $MRUS - MarketBeat
Is Merus N.V. (2GH) stock included in top ETFs2025 Bull vs Bear & Daily Market Momentum Tracking - Newser
Can Merus N.V. stock outperform in 2025 bull marketQuarterly Growth Report & Capital Efficient Trade Techniques - Newser
Merus N.V. (MRUS): A Bull Case Theory - Finviz
Why institutional investors increase stakes in Merus N.V. (2GH) stockTrade Ideas & Technical Pattern Based Signals - Newser
What makes Merus N.V. (2GH) stock appealing to growth investorsWeekly Trend Recap & High Conviction Buy Zone Picks - Newser
Genmab closes $2.5 billion notes offering to fund Merus acquisition - Investing.com
Genmab closes $2.5 billion notes offering to fund Merus acquisition By Investing.com - Investing.com South Africa
Sio Capital Management LLC Purchases Shares of 62,719 Merus N.V. $MRUS - MarketBeat
Merus (MRUS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Quadrature Capital Ltd Buys New Position in Merus N.V. $MRUS - MarketBeat
Will Merus N.V. (2GH) stock return to pre crash levelsWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - Newser
Can Merus N.V. (2GH) stock hold up in economic slowdownMarket Performance Recap & Risk Controlled Swing Trade Alerts - Newser
Merus N.V. $MRUS Shares Acquired by Ensign Peak Advisors Inc - MarketBeat
What analysts say about Merus NV stockEarnings Volatility Patterns & Free Transform Portfolio With Stocks - earlytimes.in
Merus (NASDAQ:MRUS) VP Harry Shuman Sells 8,300 Shares - MarketBeat
Responsive Playbooks and the MRUS Inflection - news.stocktradersdaily.com
Merus N.V.: VP controller Shuman sells $796k in shares By Investing.com - Investing.com Australia
ETFs investiert in Merus N.V.-Aktien - TradingView
Major Stock Sale Shakes Up Merus! - TipRanks
Merus N.V.: VP controller Shuman sells $796k in shares - Investing.com
Finance Watch: Lilly Toes The $1 Trillion Valuation Line - Citeline News & Insights
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merus N V Stock (MRUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shuman Harry | VP Controller, PAO |
Nov 26 '25 |
Sale |
96.10 |
1,700 |
163,370 |
11,002 |
| Shuman Harry | VP Controller, PAO |
Nov 25 '25 |
Sale |
95.92 |
8,300 |
796,136 |
11,002 |
| Silverman Peter B. | COO & GC |
Jul 17 '25 |
Option Exercise |
24.43 |
25,000 |
610,750 |
25,000 |
| Silverman Peter B. | COO & GC |
Jul 17 '25 |
Sale |
60.00 |
25,000 |
1,500,000 |
0 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):